TY - JOUR A2 - 维尔马，苏巴C. AU - Vorovitch，米哈伊尔F. AU - Maikova，加林娜B. AU - Chernokhaeva，柳博芙L. AU - 罗曼，维克多V. AU - Karganova，加林娜G. AU - Ishmukhametov，艾达尔A. PY - 2019 DA - 2019年12月24日TI - 5323428 VL - - 两个儿童TBE为基础的疫苗对远东和欧洲的病毒亚型SP免疫原性和安全性的比较2019 AB - 最多万箱子蜱传的脑炎每年登记，发生在17岁以下的儿童，其中20％。基于所述TBEV应变Sofjin和FSME-IMMUN小型疫苗新儿科蜱-E-Vac中疫苗之间的免疫原性和安全性的比较是在斯维尔德洛区域进行。所述疫苗株从TBEV的是，在该区域占主导地位的西伯利亚亚型的菌株不同。该研究对163米1至15岁的儿童，谁按照无论是传统或快速接种时间表收到的疫苗之一进行。免疫原性是基于血清保护率和病毒中和抗体滴度评估。有在任的免疫原性，或基于远东或TBEV的欧洲亚型毒株的儿科疫苗的反应原性没有显著差异。在这两种疫苗接种时间表，在第二次注射后30天，血清保护率分别为蜱-E-Vac中100％，大于95％为FSME-IMMUN小型，而TBEV中和抗体的几何平均效价为至少2,4日志₁₀(1 : 250) for either vaccine. Fourteen days after the second injection according to the rapid schedule, seroprotection rates were significantly lower, ranging from 50% to 63% regardless of the vaccine used. The observed adverse reactions were mild or moderate for both vaccines under both vaccination schedules, with total adverse event rates of less than 25%. Reactogenicity was not associated with the gender or age of the recipients. There were no statistically significant differences in the incidence of adverse reactions between the group of subjects who were baseline seronegative or seropositive. However, 14 days after the second vaccine injection according to the rapid schedule, a statistically significant difference in nAbs titers was identified between groups of children with and without reported reactions. SN - 1687-8639 UR - https://doi.org/10.1155/2019/5323428 DO - 10.1155/2019/5323428 JF - Advances in Virology PB - Hindawi KW - ER -